Supplementary Material for

Rearranged Terpenoids from the Marine Sponge *Darwinella* cf. *oxeata* and its Predator, the Nudibranch *Felimida grahami*

Maria Camila A. Ramirez, Juliana R. Gubiani, Lizbeth L. L. Parra, Mario F. C. Santos, David E. Williams, Daiane D. Ferreira, Juliana T. Mesquita, Andre G. Tempone, Antonio G. Ferreira, Vinícius Padula, Eduardo Hajdu, Raymond J. Andersen, Roberto G. S. Berlinck*

Page S2 - 1. Detailed Isolation Procedure for Compounds **2** – **7**.

Page S4 – 2. Schemes of Isolation Procedures for Compounds **2** – **5**.

Page S6 - **Figure S1**. Separation scheme for the isolation of oxeatamides derivatives **2** - **5**.

Page S7 - 3. Procedure for the anti-*Trypanosoma cruzi* bioassay and mammalian cytotoxicity

Page S9 - **Figure S2**. ^{1}H NMR Spectrum of the Oxeatine (**2**) in $CDCl_3$ at 600 MHz.

Page S10 - **Figure S3**. ^{13}C NMR Spectrum of the Oxeatine (**2**) in $CDCl_3$ at 150 MHz.

Page S11 - **Figure S4**. Expansion of the ^{13}C NMR Spectrum of oxeatine (**2**) in $CDCl_3$ at 150 MHz.

Page S11 - **Figure S5**. Expansion of the ^{13}C NMR Spectrum of oxeatine (**2**) in $CDCl_3$ at 150 MHz.

Page S12 - **Figure S6**. ^{1}H NMR Spectrum of Oxeatamide H (**3**) in $CDCl_3$ at 600 MHz.

Page S13 - **Figure S7**. ^{13}C NMR Spectrum of Oxeatamide H (**3**) in $CDCl_3$ at 150 MHz.

Page S14 - **Figure S8**. ^{1}H NMR Spectrum of Oxeatamide I (**4**) in DMSO-d_6 at 600 MHz.

Page S15 - **Figure S9**. ^{13}C NMR Spectrum of the Oxeatamide I (**4**) in DMSO-d_6 at 150 MHz.

Page S16 - **Figure S10**. ^{1}H NMR Spectrum of the Oxeatamide J (**5**) in acetone-d_6 at 600 MHz.

Page S17 - **Figure S11**. ^{1}H NMR Spectrum of the Oxeatamide J (**5**) in DMSO-d_6 at 600 MHz.

Page S18 - **Figure S12**. UPLC-QTOF trace of the extract of the mantle of *F. grahami* with rearranged diterpenes isolated from *Darwinella* cf. *oxeata*.

1. Detailed Isolation Procedure for Compounds **2** – **7**.

Specimens of *D. oxeata* were removed from the EtOH (300 mL) and extracted with MeOH (3 x 300 mL, 30 min in an utrasound bath). The extracts were pooled and evaporated. The resulting organic extract was suspended in 95% MeOH and partitioned with hexane (3 x 200 mL). After evaporation, the MeOH extract was suspended in H_2O and extracted with EtOAc (3 x 500 mL). The EtOAc extract was evaporated to give 1.79 g of crude material.

The EtOAc fraction (1.79 g) was fractionated by Sephadex LH20 (MeOH) column chromatography, to give six fractions: E1A-1 (385.6 mg), E1A-2 (178.1 mg), E1A-3 (257.5 mg), E1A-4 (511.5 mg), E1A-5 (153.2 mg) and E1A-6 (72.9 mg). The fractions were analyzed by HPLC-UV-MS, using an analytical C_{18} reversed-phase column (Waters X-Terra MS C_{18}, 3.5 μm, 2.1 x 50 mm) with a linear gradient of 1:1 MeOH/MeCN in H_2O (with 0.1% HCO_2H) as eluent, starting at 80% to 0% H_2O over 22 min, at a flow rate of 1.0 mL/min. Detection was monitored by UV between λ_{max} 200 and 400 nm and by positive ion ESIMS with a cone voltage of 25 V monitoring ions between *m/z* 180 and 700. Fractions E1A-3 and E1A-4 were pooled (769.0 mg) and subjected to a solid-phase extraction on a C_{18} reversed-phase silica-gel cartridge (10 g) eluted with 40:60, 50:50, 60:40, 70:30, 90:10 MeOH/H_2O and 100% MeOH. Six fractions were obtained: E1A-34-1 (153.4 mg), E1A-34-2 (165.4 mg), E1A-34-3 (190.9 mg), E1A-34-4 (132.9 mg), E1A-34-5 (71.2 mg) and E1A-34-6 (15.0 mg), which were analyzed by HPLC-UV-ESIMS. Fraction E1A-34-1 was further fractionated by reversed-phase HPLC (Inertsil ODS-2 SP, 5 μm, 7.6 x 250 mm, GL Sciences Inc.) using an isocratic elution with 76:24 MeOH/H_2O and 0.1% HCO_2H as eluent over 30 min, at 1.5 mL/min. Five fractions were obtained: E1A-34-11 (59.0 mg), E1A-34-12 (13.6 mg), E1A-34-13 (27.2 mg), E1A-34-14 (2.8 mg) and E1A-34-15 (4.1 mg), which were analyzed by HPLC-UV-MS. Fraction E1A-34-13 was fractionated by HPLC using a C_8 reversed-phase column (Inertsil C_8-4, 5 μm, 4.6 x 250 mm, GL Sciences Inc.) using a gradient elution from 70% MeOH/H_2O to 75% MeOH/H_2O with 0.1% HCO_2H as eluent over 15 min, at 0.8 mL/min, to give two fractions: E1A-34-13-A (5.9 mg) and E1A-34-13-B (1.3 mg). Fraction E1A-34-13-A was purified by HPLC using a C_8 reversed-phase column (Inertsil C_8-4, 5 μm, 4.6 x 250 mm, GL Sciences Inc.) and MeCN/H_2O 35:65 as eluent over 20 min, at 1.0 mL/min to give a pure sample of oxeatamide A (**6**, 4.0 mg). Fraction E1A-34-13-B was purified by HPLC using a C_{18} Inertsil ODS-EP column (5 μm, 4.6 x 250 mm) and MeCN/H_2O 45:55 as eluent over 20 min, at 1.0 mL/min, to give oxeatamide A methyl ester (**7**, 0.5 mg). Fraction E1A-34-2 (165.4 mg) was fractionated by reversed-phase HPLC (Inertsil ODS-3,

5 μm, 4.6 x 250 mm, GL Sciences Inc.) using a linear gradient from 80% MeOH/H_2O to 88% MeOH/H_2O with 0.1% HCO_2H as eluent over 25 min, at 1.0 mL/min, to give five fractions E1A-34-21 (49.6 mg), E1A-34-22 (24.3 mg), E1A-34-23 (38.1 mg), E1A-34-24 (30.4 mg) and E1A-34-25 (28.1 mg), which were analyzed by HPLC-UV-MS. Fraction E1A-34-23 was purified by HPLC using a C_{18} Inertsil ODS-3 column (5 μm, 4.6 x 250 mm) and MeOH/MeCN/H_2O 20:40:40 with 0.1% HCO_2H as eluent over 30 min, at 1.0 mL/min, to give four fractions: E1A-34-23-A (2.6 mg), E1A-34-23-B (9.7 mg), E1A-34-23-C (2.1 mg) and E1A-34-23-D (6.6 mg). Fraction E1A-34-23-B was purified by HPLC using a C_8 reversed-phase column (Inertsil C_8-4, 5 μm, 4.6 x 250 mm, GL Sciences Inc.) and MeCN/H_2O 35:65 with 0.1% HCO_2H as eluent over 20 min, at 1.0 mL/min, to give an additional amount of **6** (4.4 mg). Fraction E1A-34-23-D was purified by HPLC using a C_{18} Delta-Pak™ SP column (15 μm, 7.8 x 300 mm, Waters) and MeCN/H_2O 55:45 with 0.1% HCO_2H as eluent over 20 min, at 1.8 mL/min, to give pure sample of oxeatamide A methyl ester (**7**, 1.6 mg). Fraction E1A-34-24 was purified by HPLC using a C_{18} X-Terra column (5 μm, 4.6 x 250 mm) and MeCN/H_2O 40:60 with 0.1% HCO_2H as eluent over 40 min, at 1.0 mL/min, to give nine fractions: E1A-34-24-A (0.8 mg), E1A-34-24-B (1.4 mg), E1A-34-24-C (0.8 mg), E1A-34-24-D (1.7 mg), E1A-34-24-E (5.7 mg), E1A-34-24-F (2.7 mg), E1A-34-24-G (2.9 mg), E1A-34-24-H (4.9 mg) and E1A-34-24-I (7.5 mg). Fraction E1A-34-24-B was identified as oxeatamide H (**3**, 1.4 mg). Fraction E1A-34-25 was separated by HPLC using a C_{18} X-Terra column (5 μm, 4.6 x 250 mm) and MeCN/H_2O 50:50 with 0.1% HCO_2H as eluent over 30 min, at 1.0 mL/min, to give fraction E1A-34-25-A (5.7 mg) that was purified by HPLC using a C_{18} X-Terra column (5 μm, 4.6 x 250 mm) and MeOH/H_2O 70:30 with 0.1% HCO_2H as eluent over 15 min, at 1.0 mL/min, to give oxeatine (**2**, 1.7 mg). Fraction E1A-34-3 was purified by HPLC using a C_{18} Delta-Pak SP column (15 μm, 7.8 x 300 mm, Waters) using gradient elution from 80% to 90% MeCN/H_2O with 0.1% HCO_2H as eluent over 30 min, at 1.5 mL/min, to give five fractions: E1A-34-31 (4.1 mg), E1A-34-32 (15.1 mg), E1A-34-33 (51.1 mg), E1A-34-34 (65.8 mg) and E1A-34-35 (31.4 mg). Fraction E1A-34-33 was fractionated by HPLC using a C_{18} Delta-Pak™ SP column (15 μm, 7.8 x 300 mm, Waters) and MeCN/H_2O 65:35 with 0.1% HCO_2H as eluent over 30 min, at 1.5 mL/min, to give six fractions: E1A-34-33-A (2.1 mg), E1A-34-33-B (9.8 mg), E1A-34-33-C (3.7 mg), E1A-34-33-D (5.2 mg), E1A-34-33-E (14.5 mg) and E1A-34-33-F (2.8 mg). Fraction E1A-34-33-E was purified by HPLC using a C_{18} X-Terra column (5 μm, 4.6 x 250 mm) and MeCN/H_2O 45:55 with 0.1% HCO_2H as eluent over 20 min, at 1.2 mL/min, to give membranolide (**1**, 9.6 mg). Fraction E1A-34-4 was separated by reversed-phase HPLC (Inertsil ODS-2 SP, 5 μm, 7.6 x 250 mm, GL Sciences Inc.) using an isocratic elution of 60:40

$MeCN/H_2O$ with 0.1% HCO_2H as eluent over 30 min, at 1.5 mL/min. Five additional fractions were obtained: E1A-34-41 (3.8 mg), E1A-34-42 (2.0 mg), E1A-34-43 (3.7 mg), E1A-34-44 (3.1 mg) and E1A-34-45 (13.1 mg). Fraction E1A-34-42 was purified by HPLC using a C_{18} X-Terra column (5 µm, 4.6 x 250 mm) and $MeOH/H_2O$ 50:50 with 0.1% HCO_2H as eluent over 20 min, at 1.0 mL/min, to give an additional amount (1.2 mg) of membranolide (**1**). Fractions E1A-5 and E1A-6 were pooled (225.0 mg) and were fractionated by reversed-phase HPLC (Inertsil ODS-2 SP, 5 µm, 7.6 x 250 mm, GL Sciences Inc.) using gradient elution from 10% to 50% $MeOH/H_2O$ with 0.1% HCO_2H as eluent over 40 min, at 1.5 mL/min, to give eight fractions: E1A-56-1 (15.2 mg), E1A-56-2 (23.7 mg), E1A-56-3 (11.5 mg), E1A-56-4 (36.1 mg), E1A-56-5 (31.6 mg), E1A-56-6 (22.5 mg), E1A-56-7 (10.3 mg) and E1A-56-8 (59.8 mg). These fractions were analyzed by HPLC-UV-ESIMS and SciFinder and MarinLit databases were used for dereplication. Fraction E1A-56-8 was purified by HPLC using a C_8 reversed-phase column (Inertsil C_8-4, 5 µm, 4.6 x 250 mm, GL Sciences Inc.) and $MeCN/H_2O$ 50:50 with 0.1% HCO_2H as eluent over 45 min, at 3.0 mL/min, to give eight fractions: E1A-56-81 (14.8 mg), E1A-56-82 (8.8 mg), E1A-56-83 (10.1 mg), E1A-56-84 (0.9 mg), E1A-56-85 (2.8 mg), E1A-56-86 (3.1 mg), E1A-56-87 (1.1 mg) and E1A-56-88 (3.4 mg). Fraction E1A-56-82 was purified by HPLC using a C_{18} InertSustain column (5 µm, 4.6 x 250 mm, GL Sciences) and $MeCN/H_2O$ 40:60 as eluent over 40 min, at 1.0 mL/min, to give four fractions: E1A-56-82-A (0.7 mg), E1A-56-82-B (1.7 mg), E1A-56-82-C (1.8 mg) and E1A-56-82-D (0.5 mg). Fraction E1A-56-82-C was purified by HPLC using a C_{18} X-Terra column (5 µm, 4.6 x 250 mm) with a linear gradient of 1:1 MeOH/MeCN in H_2O (with 0.1% HCO_2H), starting at 90% to 0% H_2O over 40 min, at a flow rate of 1.0 mL/min, to give oxeatamide I (**4**, 1.2 mg). Fraction E1A-56-85 was purified by HPLC using a C_{18} X-Terra column (5 µm, 4.6 x 250 mm) with a linear gradient of 1:1 MeOH/MeCN in H_2O (with 0.1% HCO_2H), starting at 90% to 0% H_2O over 40 min, at a flow rate of 1.0 mL/min, to give oxeatamide J (**5**, 2.3 mg).

2. Schemes of Isolation Procedures for Compounds **2** – **5**.

The fraction EtOAc (1.7925 g, see Experimental Section) was separated by a series of chromatographic steps summarized in Figure S1. The specific conditions for the separations steps 1-10 are the following:

1. Sephadex LH20 (MeOH).

2. Column chromatography C18 reversed phase gradient MeOH in H_2O from 60:40 to 100% MeOH

3. HPLC condition 1: C_{18} reversed-phase column (Inertsil ODS-3, 5 µm, 4.6 x 250 mm, GL Sciences Inc.) linear gradient of 80% to 88% MeOH/H_2O with 0.1% formic acid over 25 min; flow rate: 1.0 mL/min.

4. HPLC condition 2: C_{18} X-Terra column (5 µm, 4.6 x 250 mm) isocratic 40:60 MeCN/H_2O with 0.1% formic acid over 40 min; flow rate: 1.0 mL/min.

5. HPLC condition 3: C_{18} X-Terra column (5 µm, 4.6 x 250 mm) isocratic 1:1 MeCN/H_2O with 0.1% formic acid over 30 min; flow rate: 1.0 mL/min.

6. HPLC condition 4: C_{18} X-Terra column (5 µm, 4.6 x 250 mm) isocratic 70:30 MeOH/H_2O with 0.1% formic acid over 15 min; flow rate: 1.0 mL/min.

7. HPLC condition 5: C_{18} reversed-phase column (Inertsil ODS-2 SP, 5 µm, 7.6 x 250 mm, GL Sciences Inc.) gradient of 10% to 50% MeOH/H_2O with 0.1% formic acid over 40 min; flow rate: 1.5 mL/min.

8. HPLC condition 6: C_8 reversed-phase column (Inertsil C8-4, 5 µm, 4.6 x 250 mm, GL Sciences Inc.) isocratic 1:1 MeCN/H_2O with 0.1% formic acid over 45 min; flow rate: 3.0 mL/min.

9. HPLC condition 7: C_{18} InertSustain column (5 µm, 4.6 x 250 mm, GL Sciences) isocratic 40:60 MeCN/H_2O over 40 min; flow rate: 1.0 mL/min.

10. HPLC condition 8: C_{18} X-Terra column (5 µm, 4.6 x 250 mm) linear gradient of 1:1 MeOH/MeCN in H_2O (with 0.1% formic acid), starting at 90% until 0% H_2O over 40 min; flow rate: 1.0 mL/min.



Figure S1. Separation scheme for the isolation of oxeatine (**2**) and oxeatamides H – J (**3** – **5**).

3. Procedure for the anti-*Trypanosoma cruzi* bioassay

BALB/c mice were obtained by the animal breeding facility at the Adolfo Lutz Institute-SP, Brazil. The animals were maintained in sterilized cages under a controlled environment and received water and food *ad libitum*. Animal procedures were performed with the approval of the Research Ethics Commission (project CEUA/IAL-Pasteur 02/2011).

Trypomastigotes of *Trypanosoma cruzi* (Y strain) were maintained in Rhesus monkey kidney cells (LLC-MK2-ATCC CCL 7), cultivated in RPMI-1640 medium supplemented with 2% FBS at 37 °C in a 5% CO_2-humidified incubator. Macrophages were collected from the peritoneal cavity of BALB/c mice by washing them with RPMI-1640 medium supplemented with 10% FBS and were maintained at 37 °C in a 5% CO_2-humidified incubator. The murine fibroblasts (NCTC clone 929, ATCC) were maintained in RPMI-1640 supplemented with 10% FBS at 37 °C in a humidified atmosphere containing 5% CO_2.

In order to determine the 50% inhibitory concentration (IC_{50}) against *T. cruzi*, trypanosomes were obtained from LLC-MK2 cultures, seeded at $1x10^6$ cells/well in 96-well plates and incubated with samples (maximal concentration of 100 µM) during 24 h at 37 °C in a 5% CO_2-humidified incubator. The viability was determined by determined by the resazurin assay (0.011% in PBS).[1]

The activity against intracellular parasites was determined in infected macrophages. Macrophages obtained as previously described and seeded for 24 h at $1x10^5$ cells/well in 16-well slide chambers (Nunc). Trypomastigotes of *T. cruzi* obtained from LLC-MK2 cultures were added to the macrophages at a ratio of 1:5 (macrophage/parasite) for 4 h at 37 ºC in 5% CO_2 atmosphere. Non-internalized parasites were removed by washing once with medium and the cells were then incubated with the test samples (maximal concentration of 55 µM) during 48 h for *T. cruzi* treatment at 37 ºC in 5% CO_2 atmosphere. Benznidazol were used as the standard drug control. At the end of the assay, the cells were fixed in MeOH, stained with Giemsa and observed under a light microscope. The parasite burden was determined by the following infection index: mean number of infected macrophages x mean number of amastigotes per macrophage / 100 macrophages. At least 200 macrophages were counted per tested concentration.

Cytotoxicity on Mammalian Cells

NCTC cells-clone L929 ($6x10^4$ cells/well) were seeded and incubated with test samples (maximal concentration of 150 µM)) for 48 h at 37 ºC in a 5% CO_2 incubator and the 50% cytotoxic concentration (CC_{50}) was determined by the MTT assay, as above described. For all assays, the optical density was

determined in a plate spectrophotometer reader (FilterMax F5, Molecular Devices, USA) at 570 nm. Mammalian cells were incubated without test samples and used as the viability control (100% viability).

Reference

1. Martins, L. F; Mesquita, J. T.; Pinto, E. G.; Costa-Silva, T. A.; Borborema, S. E.; Galisteo Junior, A. J.; Neves, B. J.; Andrade, C. H.; Shuhaib, Z. A.; Bennett, E. L.; Black, G. P.; Harper, P. M.; Evans, D. M.; Fituri, H. S.; Leyland, J. P.; Martin, C.; Roberts, T. D.; Thornhill, A. J.; Vale, S. A.; Howard-Jones, A.; Thomas, D. A.; Williams, H. L.; Overman, L. E.; Berlinck, R. G. S.; Murphy, P. J.; Tempone, A. G. *J. Nat. Prod*. **2016**, *79*, 2202–2210.



Figure S2. ^{1}H NMR Spectrum of the Oxeatine (**2**) in $CDCl_3$ at 600 MHz.



Figure S3. ^{13}C NMR Spectrum of oxeatine (**2**) in $CDCl_3$ at 150 MHz.



Figure S4. Expansion of the ^{13}C NMR Spectrum of oxeatine (**2**) in $CDCl_3$ at 150 MHz.



Figure S5. Expansion of the ^{13}C NMR Spectrum of oxeatine (**2**) in $CDCl_3$ at 150 MHz.



Figure S6. ^{1}H NMR Spectrum of oxeatamide H (**3**) in $CDCl_3$ at 600 MHz.



Figure S7. ^{13}C NMR Spectrum of oxeatamide H (**3**) in $CDCl_3$ at 150 MHz.



Figure S8. ¹H NMR Spectrum of oxeatamide I (**4**) in DMSO-d_6 at 600 MHz.



Figure S9. ^{13}C NMR Spectrum of the oxeatamide I (**4**) in DMSO-d_6 at 150 MHz.



Figure S10. ^{1}H NMR Spectrum of the oxeatamide J (**5**) in acetone-d_6 at 600 MHz.



Figure S11. ^{1}H NMR Spectrum of the oxeatamide J (**5**) in DMSO-d_6 at 600 MHz.



Figure S12. UPLC-QTOF trace of the extract of the mantle of *F. grahami* with rearranged diterpenes isolated from *Darwinella* cf. *oxeata*. Line A: mantle extract of *F. grahami*. Line B: Membranolide (**1**). Line C: Oxeatamide A methyl ester (**7**). Line D: Oxeatamide J (**5**). Line E: Oxeatamide I (**4**). Line F: Oxeatine (**2**). Conditions: Acquity UPLC BEH C_{18} (1.7 µm, 2.1 × 100 mm) column; eluent: gradient of MeCN (0.01% HCO_2H) in H_2O (0.01% HCO_2H), starting at 10% to 98% MeCN (0.01% HCO_2H) in 8 min. Detection: MSE continuum during 2 min, *m/z* 185−1.000 molecular weight range; detection mode: ESI(+); scan time: 0.2 s; ramp collision energy: 20−30 V.